

a pharmaceutically acceptable form, and an effective, non-toxic and pharmaceutically acceptable amount of insulin to a mammal in need thereof.

17. (New) A method according to claim 16, which comprises administering 2 to 4 mg, 4 to 8 mg, or 8 to 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

18. (New) A method according to claim 17, which comprises administering 2 to 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

19. (New) A method according to claim 17, which comprises administering 4 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

20. (New) A method according to claim 17, which comprises administering 8 to 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

21. (New) A method according to claim 16, which comprises administering 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

22. (New) A method according to claim 16, which comprises administering 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

23. (New) A method according to claim 16, which comprises administering 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

24. (New) A method according to claim 16, which comprises administering a unit dosage form of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

25. (New) A method according to claim 16, which comprises administering a unit dosage form comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

B1
26. (New) A method according to claim 25, comprising administering a unit dosage form comprising 1 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

27. (New) A method according to claim 25, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

28. (New) A method according to claim 25, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

29. (New) A method according to claim 25, comprising administering a unit dosage form comprising 8 mg of said 5-[4-[2-(N-methyl-

N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

30. (New) A method according to claim 25, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

31. (New) A method according to claim 25, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

32. (New) A method according to claim 25, wherein said unit dosage form is a tablet or a capsule.

33. (New) A method according to claim 16, which comprises co-administering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

34. (New) A method according to claim 33, which comprises administering a formulation which comprises both of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

35. (New) A method according to claim 33, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

36. (New) A method according to claim 16, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-

pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

37. (New) A method according to any one of claims 16-36, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

38. (New) A method according to claim 37, wherein said pharmaceutically acceptable salt is a maleate salt.

39. (New) A method according to any one of claims 16-36, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

40 (New) A method according to any one of claims 16-36, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

41. (New) A method according to claim 39, wherein said pharmaceutically acceptable solvate is a hydrate.

42. (New) A method according to claim 40, wherein said pharmaceutically acceptable solvate is a hydrate.

43. (New) A method for the treatment of Type II diabetes in a mammal, which method comprises administering 1 to 12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and an effective, non-toxic and pharmaceutically acceptable amount of insulin to a mammal in need thereof.

44. (New) A method according to claim 43, which comprises administering 2 to 4 mg, 4 to 8 mg, or 8 to 12 mg of said 5-[4-[2-(N-methyl-

N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

45. (New) A method according to claim 44, which comprises administering 2 to 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

46. (New) A method according to claim 44, which comprises administering 4 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

47. (New) A method according to claim 44, which comprises administering 8 to 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

48. (New) A method according to claim 43, which comprises administering 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

49. (New) A method according to claim 43, which comprises administering 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

50. (New) A method according to claim 43, which comprises administering 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

51. (New) A method according to claim 43, which comprises administering a unit dosage form of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

52. (New) A method according to claim 43, which comprises administering a unit dosage form comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

53. (New) A method according to claim 52, comprising administering a unit dosage form comprising 1 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

B1
54. (New) A method according to claim 52, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

55. (New) A method according to claim 52, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

56. (New) A method according to claim 52, comprising administering a unit dosage form comprising 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

57. (New) A method according to claim 52, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-

N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

58. (New) A method according to claim 52, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

59. (New) A method according to claim 52, wherein said unit dosage form is a tablet or a capsule.

60. (New) A method according to claim 43, which comprises co-administering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

61. (New) A method according to claim 60, which comprises administering a formulation which comprises both of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

62. (New) A method according to claim 60, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

63. (New) A method according to claim 43, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

64. (New) A method according to any one of claims 43-63, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

65. (New) A method according to claim 64, wherein said pharmaceutically acceptable salt is a maleate salt.

66. (New) A method according to any one of claims 43-63, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

67. (New) A method according to any one of claims 43-63, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

68. (New) A method according to claim 66, wherein said pharmaceutically acceptable solvate is a hydrate.

69. (New) A method according to claim 67, wherein said pharmaceutically acceptable solvate is a hydrate.

70. (New) A method according to claim 43, wherein said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is administered in a pharmaceutically acceptable composition comprising sodium starch glycollate, hydroxypropyl methylcellulose, microcrystalline cellulose and lactose monohydrate.

REMARKS

The claims are 16-70 with claims 16 and 43 being independent. Claims 1-11 and 13-15 have been canceled without prejudice or disclaimer. Support for claims 16-70 may be found throughout the specification. For example, support for claims 16-23 may be found in original claims 1-12. Support for claims 43-50 may